Shareholder Approval of Business Combination Vancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that at an annual and special meeting of the Company held on August 3, 2021, shareholders of the Company have approved, among other matters, iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").
The Company expects trading of the shares of the combined company to begin trading on the TSX Venture Exchange as Satellos Bioscience Inc. under the symbol MSCL during the week of August 9, 2021.
William Jarosz, the CEO of iCo noted, "The Transaction was approved by 98.5% of the shareholders voting at the annual and special meeting of the shareholders. The shareholders recognized the value that the Satellos assets bring to the combined business and the extraordinary opportunities they offer for the future. We are grateful for this support and will work diligently going forward to ensure that this support is warranted. We are very excited about what lies ahead for iCo's shareholders."